We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ZEJULA (Takeda Pharmaceuticals Australia Pty Ltd)
Product name
ZEJULA
Date registered
Evaluation commenced
Decision date
Approval time
180 working days (255)
Active ingredients
niraparib (as tosilate monohydrate)
Registration type
NCE/NBE
Indication
ZEJULA (capsules) is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.